Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Orchard Therapeutics plc ORTX
$5.21
-$0.27 (-5.10%)
На 17:46, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
101191200.00000000
-
week52high
7.20
-
week52low
3.60
-
Revenue
6986000
-
P/E TTM
0
-
Beta
0.90764200
-
EPS
-11.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
06 мар 2023 г. в 13:30
Описание компании
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Barclays | Overweight | Overweight | 13 мая 2022 г. |
| SMBC Nikko | Neutral | Outperform | 01 апр 2022 г. |
| Cowen & Co. | Market Perform | Outperform | 31 мар 2022 г. |
| JP Morgan | Underweight | Neutral | 16 ноя 2021 г. |
| Oppenheimer | Outperform | Outperform | 05 ноя 2021 г. |
| SMBC Nikko | Neutral | Outperform | 29 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Gaspar Bobby | A | 55006 | 55006 | 04 окт 2022 г. |
| Gaspar Bobby | A | 0 | 55006 | 04 окт 2022 г. |
| Gaspar Bobby | A | 850000 | 850000 | 04 окт 2022 г. |
| Gaspar Bobby | A | 300000 | 300000 | 04 окт 2022 г. |
| Gaspar Bobby | A | 200000 | 200000 | 04 окт 2022 г. |
| Gaspar Bobby | A | 50000 | 50000 | 04 окт 2022 г. |
| THOMAS FRANK E | A | 75000 | 75000 | 04 окт 2022 г. |
| THOMAS FRANK E | A | 457811 | 457811 | 04 окт 2022 г. |
| THOMAS FRANK E | A | 27731 | 27731 | 04 окт 2022 г. |
| THOMAS FRANK E | A | 0 | 27731 | 04 окт 2022 г. |
Новостная лента
Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates
Seeking Alpha
24 апр 2023 г. в 17:38
Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates.
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
GlobeNewsWire
30 мар 2023 г. в 07:00
BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the Guggenheim Genomic Medicines and Rare Disease Day on Tuesday, April 4, 2023 at 1:35pm ET.
Orchard Therapeutics plc (ORTX) Q4 2022 Earnings Call Transcript
Seeking Alpha
10 мар 2023 г. в 15:17
Orchard Therapeutics plc (NASDAQ:ORTX ) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ET Company Participants Bobby Gaspar - Chief Executive Officer Frank Thomas - President and COO Braden Parker - Chief Commercial Officer Leslie Meltzer - Chief Medical Officer Conference Call Participants Dae Gon Ha - Stifel Hartaj Singh - Oppenheimer Brendan Smith - TD Cowen David Hoang - SMBC Nikko Securities Robert Finke - Guggenheim Securities Pete Stavropoulos - Cantor Fitzgerald Bobby Gaspar Hello, everyone. I'm Bobby Gaspar, CEO and Co-Founder of Orchard.
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
GlobeNewsWire
03 мар 2023 г. в 07:00
BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences:
5 Hot Penny Stocks Exploding After News This Week
PennyStocks
05 янв 2023 г. в 09:39
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.